Zheng Quan Shi Bao Wang·2025-06-03 10:43Core Viewpoint - The generic drug consistency evaluation concept has seen a notable increase in stock prices, with a rise of 3.08%, ranking it as the 9th highest among concept sectors as of June 3 [1][2]. Group 1: Stock Performance - Within the generic drug consistency evaluation sector, 116 stocks experienced gains, with notable performers including Huana Pharmaceutical and Beilu Pharmaceutical, both reaching a 20% limit up [1]. - Other significant gainers included Wantong Pharmaceutical (10.06%), Qianhong Pharmaceutical (10.05%), and Anglikang (10.03%) [3][6]. - Conversely, stocks such as *ST Suwu, Borui Pharmaceutical, and Haishike saw declines of 4.78%, 2.48%, and 2.18% respectively [1][9]. Group 2: Capital Inflow - The generic drug consistency evaluation sector attracted a net inflow of 584 million yuan, with 58 stocks receiving capital inflow, and 5 stocks exceeding 50 million yuan in net inflow [2]. - Leading the net inflow was Huahai Pharmaceutical with 266 million yuan, followed by Qianhong Pharmaceutical (201 million yuan) and Beilu Pharmaceutical (104 million yuan) [2][3]. Group 3: Capital Flow Ratios - Stocks such as Anglikang, Wantong Pharmaceutical, and Beilu Pharmaceutical had the highest net inflow ratios at 23.94%, 22.75%, and 15.95% respectively [3]. - Huahai Pharmaceutical recorded a daily turnover rate of 7.71% with a net inflow ratio of 12.53% [3].